Carbylan Therapeutics's (CBYL) Phase 3 Trial of Hydros-TA in Patients With OA of Knee Meets One Primary Endpoint, Misses Second Primary Endpoint
Tweet Send to a Friend
(Updated - February 1, 2016 5:24 PM EST)Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
